Expression of osteonectin and matrix Gla protein in scleroderma patients with and without calcinosis

Rheumatology

Volumn 45, Issue 11, 2006, Pages 1349-1355

  Davies, C A ^a   Jeziorska, M ^a   Freemont, A J ^a   Herrick, Ariane L ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b HOPE HOSPITAL   (United Kingdom)

Author keywords

Immunohistochemistry; Matrix Gla protein; Osteonectin; Skin; Systemic sclerosis

Indexed keywords

4 CARBOXYGLUTAMIC ACID; OSTEONECTIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DERMIS; ENDOTHELIUM CELL; FEMALE; FOREARM; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROVASCULATURE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PUNCH BIOPSY; QUANTITATIVE ANALYSIS; SKIN BIOPSY; SKIN CALCIFICATION; SKIN FIBROBLAST; SYSTEMIC SCLEROSIS; UPREGULATION; VASCULAR ENDOTHELIUM;

ADULT; CALCINOSIS; CALCIUM-BINDING PROTEINS; ENDOTHELIUM, VASCULAR; EXTRACELLULAR MATRIX PROTEINS; FEMALE; FIBROBLASTS; FOREARM; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; OSTEONECTIN; SCLERODERMA, SYSTEMIC; SKIN; SKIN DISEASES;

EID: 33750215294     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kei277     Document Type: Article

References (45)

1. Steen VD, Ziegler GL, Rodnan GP, Medsger TA Jr. Clinical and laboratory associations of anticentromere antibody in patients with progressive systemic sclerosis. Arthritis Rheum 1984;27:125-31.
2. Chamberlain AJ, Walker NPJ. Successful palliation and significant remission of cutaneous calcinosis in CREST syndrome with carbon dioxide laser. Dermatol Surg 2003;29:968-70.
3. Bostrom K. Insights into the mechanism of vascular calcification. Am J Cardiol 2001;88: 20E-22E.
4. Doherty TM, Asotra K, Fitzpatrick LA et al. Calcification in atherosclerosis: Bone biology and chronic inflammation at the arterial crossroads. Proc Natl Acad Sci USA 2003;100:11201-6.
5. Vermeer C, Braam L. Role of K vitamins in the regulation of tissue calcification. J Bone Miner Metab 2001;19:201-6.
6. Schinke T, Karsenty G. Vascular calcification - a passive process in need of inhibitors. Nephrol Dial Transplant 2000;15:1272-4.
7. Jeziorska M, McCollum C, Wooley DE. Observations on bone formation and remodelling in advanced atherosclerotic lesions of human carotid arteries. Virchows Arch 1998;433:559-65.
8. Bostrom K, Watson KE, Horn S, Wortham C, Herman IM, Demer LL. Bone morphogenetic protein expression in human atherosclerotic lesions. J Clin Invest 1993;91:1800-9.
9. Shanahan CM, Cary NR, Metcalfe JC, Weissberg PL. High expression of genes for calcification-regulating proteins in human atherosclerotic plaques. J Clin Invest 1994;93:2393-402.
10. Bini A, Mann KG, Kudryk BJ, Schoen FJ. Noncollagenous bone matrix proteins, calcification, and thrombosis in carotid artery atherosclerosis. Arterioscler Thromb Vase Biol 1999;19: 1852-61.
11. Dhore CR, Cleutjens JP, Lutgens E et al. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2001;21:1998-2003.
12. Spronk HM, Soute BA, Schurgers LJ et al. Matrix Gla protein accumulates at the border of regions of calcification and normal tissue in the media of the arterial vessel wall. Biochem Biophys Res Comm 2001;289:485-90.
13. Canfield AE, Farrington C, Dziobon MD et al. The involvement of matrix glycoproteins in vascular calcification and fibrosis: An immunohistochemical study. J Pathol 2002;196:228-34.
14. Sweatt A, Sane DC, Hutson SM, Wallin R. Matrix Gla protein (MGP) and bone morphogenetic protein-2 in aortic calcified lesions of aging rats. J Thromb Haemost 2003;1:178-85.
15. Zebboudj AF, Shin V, Bostrom K. Matrix GLA protein and BMP-2 regulate osteoinduction in calcifying vascular cells. J Cell Biochem 2003;90:756-65.
16. Termine JD, Kleinman HK, Whitson SW, Conn KM, McGarvey ML, Martin GR. Osteonectin, a bone-specific protein linking mineral to collagen. Cell 1981;26:99-105.
17. Motamed K. SPARC (osteonectin/BM-40). Int J Biochem Cell Biol 1999;31:1363-6.
18. Yan Q, Sage EH. SPARC, a matricellular glycoprotein with important biological functions. J Histochem Cytochem 1999;47: 1495-506.
19. Brekken RA, Sage EH. SPARC, a matricellular protein: At the crossroads of cell-matrix. Matrix Biol J Int Soc Matrix Biol 2000; 19:569-80.
20. Vuorio T, Kahari VM, Black C, Vuorio E. Expression of osteonectin, decorin, and transforming growth factor-beta 1 genes in fibroblasts cultured from patients with systemic sclerosis and morphea. J Rheumatol 1991;18:247-51.
21. Macko RF, Gelber AC, Young BA et al. Increased circulating concentrations of the counteradhesive proteins SPARC and thrombospondin-1 in systemic sclerosis (scleroderma). Relationship to platelet and endothelial cell activation. J Rheumatol 2002;29: 2565-70.
22. Zhou X, Tan FK, Reveille JD et al. Association of novel polymorphisms with the expression of SPARC in normal fibroblasts and with susceptibility to scleroderma. Arthritis Rheum 2002;46: 2990-9.
23. Lagan AL, Pantelidis P, Renzoni EA et al. Single-nucleotide polymorphisms in the SPARC gene are not associated with susceptibility to scleroderma. Rheumatology 2005;44:197-201.
24. Lian JB, Skinner M, Glimcher MJ, Gallop P. The presence of gamma-carboxyglutamic acid in the proteins associated with ectopic calcification. Biochem Biophys Res Commun 1976; 73:349-55.
25. Hauschka PV, Lian JB, Cole DE, Gundberg CM. Osteocalcin and matrix Gla protein: Vitamin K-dependent proteins in bone. Physiol Rev 1989;69:990-1047.
26. Loeser R, Carlson CS, Tulli H, Jerome WG, Miller L, Wallin R. Articular-cartilage matrix gamma-carboxyglutamic acid-containing protein. Characterization and immunolocalization. Biochem J 1992; 282:1-6.
27. Wallin R, Cain D, Sane DC. Matrix Gla protein synthesis and gamma-carboxylation in the aortic vessel wall and proliferating vascular smooth muscle cells - a cell system which resembles the system in bone cells. Thromb Haemost 1999;82:1764-7.
28. Luo G, Duey P, McKee MD et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 1997;386:78-81.
29. Proudfoot D, Skepper JN, Shanahan CM, Weissberg PL. Calcification of human vascular cells in vitro is correlated with high levels of matrix Gla protein and low levels of osteopontin expression. Arterioscler Thromb Vasc Biol 1998;18:379-88.
30. Doherty MJ, Ashton BA, Walsh S, Beresford JN, Grant ME, Canfield AE. Vascular pericytes express osteogenic potential in vitro and in vivo. J Bone Miner Res 1998;13:828-38.
31. Canfield AE, Doherty MJ, Kelly V et al. Matrix Gla protein is differentially expressed during the deposition of a calcified matrix by vascular pericytes. FEBS Lett 2000;487:267-71.
32. LcRoy EC, Black C, Fleischmajer R et al. Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis. J Rheumatol 1988; 15:202-5.
33. Porter PL, Sage EH, Lane TF, Funk SE, Gown AM. Distribution of SPARC in normal and neoplastic human tissue. J Histochem Cytochem 1995;43:791-800.
34. Hunzelmann N, Hafner M, Anders S, Krieg T, Nischt R. BM-40 (osteonectin, SPARC) is expressed both in the epidermal and in the dermal compartment of adult human skin. J Invest Dermatol 1998; 110:122-6.
35. Meier M, Weng LP, Alexandrakis E, Ruschoff J, Goeckenjan G. Tracheobronchial stenosis in Keutel syndrome. Eur Respir J 2001; 17:566-9.
36. Wallin R, Cain D, Hutson SM, Sane DC, Loeser R. Modulation of the binding of matrix Gla protein (MGP) to bone morphogenetic protein-2 (BMP-2). Thromb Haemost 2000;84:1039-44.
37. Wallin R, Wajih N, Greenwood GT, Sane DC. Arterial calcification: A review of mechanisms, animal models, and the prospects for therapy. Med Res Rev 2001;21:274-301.
38. Zebboudj AF, Imura M, Bostrom K. Matrix GLA protein, a regulatory protein for bone morphogenetic protein-2. J Biol Chem 2002;277:4388-94.
39. Lau CS, Bridges AB, Muir A, Scott N, Bancroft A, Belch JJ. Further evidence of increased polymorphonuclear cell activity in patients with Raynaud's phenomenon. Br J Rheumatol 1992;31: 375-80.
40. Herrick AL, Rieley F, Schofield D, Hollis S, Braganza JM, Jayson MI. Micronutrient antioxidant status in patients with primary Raynaud's phenomenon and systemic sclerosis. J Rheumatol 1994; 21:1477-83.
41. Bruckdorfer KR, Hillary JB, Bunce T, Vancheeswaran R, Black CM. Increased susceptibility to oxidation of low-density lipoproteins isolated from patients with systemic sclerosis. Arthritis Rheum 1995;38:1060-7.
42. Stein CM, Tanner SB, Awad JA, Roberts LJ, Morrow JD. Evidence of free radical-mediated injury (isoprostane overproduction) in scleroderma. Arthritis Rheum 1996;39:1146-50.
43. Denton CP, Bunce TD, Darado MB et al. Probucol improves symptoms and reduces lipoprotein oxidation susceptibility in patients with Raynaud's phenomenon. Rheumatology 1999;38:309-15.
44. Herrick AL, Matucci-Cerinic M. The emerging problem of oxidative stress and the role of antioxidants in systemic sclerosis. Clin Exp Rheumatol 2001;19:4-8.
45. Vayssairat M, Hidouche D, Abdoucheli-Baudot N, Gaitz JP. Clinical significance of subcutaneous calcinosis in patients with systemic sclerosis. Does diltiazem induce its regression? Ann Rheum Dis 1998;57:252-4.